Pedrero Juana Maria Garcia, Carracedo Dario Garcia, Pinto Cristina Muñoz, Zapatero Agustín Herrero, Rodrigo Juan Pablo, Nieto Carlos Suarez, Gonzalez Maria Victoria
Instituto Universitario de Oncologia del Principado de Asturias (IUOPA), Universidad de Oviedo, 6a planta C/Julián Clavería s/n, 33006 Oviedo, Asturias, Spain.
Int J Cancer. 2005 Mar 20;114(2):242-8. doi: 10.1002/ijc.20711.
We investigated the status of the PI 3-kinase/AKT/PTEN signaling pathway in a series of 117 head and neck squamous cell carcinomas (HNSCC) in a search for molecular alterations in genes/proteins with potential prognostic value. For this purpose, PIK3CA and AKT2 gene amplification was assessed by multiplex and Quantitative Real-Time PCR. Protein expression of AKT, p-AKT, p110alpha and PTEN was determined by Western blot. PTEN allelic loss was evaluated by microsatellite analysis. PTEN-exon 5 was screened for point mutations by PCR-SSCP. Homozygous deletions were determined by multiplex PCR. PIK3CA gene was amplified in 43/117 (37%) fresh tumor samples, a frequency that did not differ from that found in archival premalignant tissues: 15/38 (39%); 12/40 (30%) fresh tumors harbored AKT2 gene amplification. AKT was found activated in 6/36 (17%) fresh tumor samples, when compared to their normal tissue counterparts. Of these 6 cases, 1 showed p110alpha overexpression and 5 displayed PTEN protein downregulation. Neither allelic loss (found in 11/77 informative cases) nor point mutations or homozygous deletions accounted for the reduced PTEN protein expression observed in our tumor series. The histologically normal mucosa of 4 patients displayed some of the molecular alterations analyzed. Dysregulation of the PI 3-K/AKT/PTEN pathway might contribute to early HNSCC tumorigenesis and might constitute a potential clinical target. Overall, 17/36 (47%) cases showed at least 1 of the molecular alterations studied here, which makes the PI 3-kinase-initiated signaling pathway one of the most frequently altered in HNSCC.
我们研究了117例头颈部鳞状细胞癌(HNSCC)中PI 3-激酶/AKT/PTEN信号通路的状态,以寻找具有潜在预后价值的基因/蛋白质中的分子改变。为此,通过多重和定量实时PCR评估PIK3CA和AKT2基因扩增。通过蛋白质印迹法测定AKT、p-AKT、p110α和PTEN的蛋白表达。通过微卫星分析评估PTEN等位基因缺失。通过PCR-SSCP筛选PTEN外显子5的点突变。通过多重PCR确定纯合缺失。在43/117(37%)的新鲜肿瘤样本中检测到PIK3CA基因扩增,这一频率与存档的癌前组织中发现的频率无差异:15/38(39%);12/40(30%)的新鲜肿瘤存在AKT2基因扩增。与正常组织对应物相比,在6/36(17%)的新鲜肿瘤样本中发现AKT被激活。在这6例病例中,1例显示p110α过表达,5例显示PTEN蛋白下调。在我们的肿瘤系列中观察到的PTEN蛋白表达降低,既不是由等位基因缺失(在11/77例信息丰富的病例中发现),也不是由点突变或纯合缺失所致。4例患者的组织学正常黏膜显示出一些所分析的分子改变。PI 3-K/AKT/PTEN通路的失调可能有助于早期HNSCC的肿瘤发生,并可能构成一个潜在的临床靶点。总体而言,17/36(47%)的病例显示至少有1种本文研究的分子改变,这使得PI 3-激酶启动的信号通路成为HNSCC中最常发生改变的信号通路之一。